Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration

dc.contributor.authorAbrego Escobar, Guadalupe
dc.contributor.authorAlvarado, Helen
dc.contributor.authorSouto, Eliana B.
dc.contributor.authorGuevara, Bessy
dc.contributor.authorHalbaut, Lyda
dc.contributor.authorParra Coca, Alexander
dc.contributor.authorCalpena Campmany, Ana Cristina
dc.contributor.authorGarcía López, María Luisa
dc.date.accessioned2015-07-29T08:44:46Z
dc.date.available2016-02-11T23:01:52Z
dc.date.issued2015-02-11
dc.date.updated2015-07-29T08:44:46Z
dc.description.abstractTwo optimized pranoprofen-loaded poly-L-lactic-co glycolic acid (PLGA) nanoparticles (PF-F1NPs; PF- 39 F2NPs) have been developed and further dispersed into hydrogels for the production of semi-solid formu- 40 lations intended for ocular administration. The optimized PF-NP suspensions were dispersed in freshly 41 prepared carbomer hydrogels (HG_PF-F1NPs and HG_PF-F2NPs) or in hydrogels containing 1% azone 42 (HG_PF-F1NPs-Azone and HG_PF-F2NPs-Azone) in order to improve the ocular biopharmaceutical profile 43 of the selected non-steroidal anti-inflammatory drug (NSAID), by prolonging the contact of the pranopro- 44 fen with the eye, increasing the drug retention in the organ and enhancing its anti-inflammatory and 45 analgesic efficiency. Carbomer 934 has been selected as gel-forming polymer. The hydrogel formulations 46 with or without azone showed a non-Newtonian behavior and adequate physicochemical properties for 47 ocular instillation. The release study of pranoprofen from the semi-solid formulations exhibited a sus- 48 tained release behavior. The results obtained from ex vivo corneal permeation and in vivo anti-inflamma- 49 tory efficacy studies suggest that the ocular application of the hydrogels containing azone was more 50 effective over the azone-free formulations in the treatment of edema on the ocular surface. No signs of 51 ocular irritancy have been detected for the produced hydrogels.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec647946
dc.identifier.issn0939-6411
dc.identifier.pmid25681744
dc.identifier.urihttps://hdl.handle.net/2445/66632
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1016/j.ejpb.2015.01.026
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics, 2015
dc.relation.urihttp://dx.doi.org/10.1016/j.ejpb.2015.01.026
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
dc.subject.classificationAntiinflamatoris no esteroïdals
dc.subject.classificationNanopartícules
dc.subject.classificationTerapèutica oftalmològica
dc.subject.classificationAdministració de medicaments
dc.subject.otherNonsteroidal anti-inflammatory agents
dc.subject.otherNanoparticles
dc.subject.otherOphthalmological therapeutics
dc.subject.otherAdministration of drugs
dc.titleBiopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
647946.pdf
Mida:
1.19 MB
Format:
Adobe Portable Document Format